Free Trial

CG Oncology (CGON) Stock Price, News & Analysis

CG Oncology logo
$26.72 +0.24 (+0.91%)
Closing price 04:00 PM Eastern
Extended Trading
$26.71 -0.01 (-0.04%)
As of 04:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About CG Oncology Stock (NASDAQ:CGON)

Key Stats

Today's Range
$26.26
$26.99
50-Day Range
$23.94
$28.46
52-Week Range
$14.80
$40.47
Volume
370,611 shs
Average Volume
967,754 shs
Market Capitalization
$2.04 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$54.30
Consensus Rating
Buy

Company Overview

CG Oncology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
25th Percentile Overall Score

CGON MarketRank™: 

CG Oncology scored higher than 25% of companies evaluated by MarketBeat, and ranked 849th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CG Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    CG Oncology has only been the subject of 4 research reports in the past 90 days.

  • Read more about CG Oncology's stock forecast and price target.
  • Earnings Growth

    Earnings for CG Oncology are expected to decrease in the coming year, from ($1.31) to ($1.77) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CG Oncology is -14.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CG Oncology is -14.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    CG Oncology has a P/B Ratio of 3.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about CG Oncology's valuation and earnings.
  • Percentage of Shares Shorted

    24.51% of the float of CG Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    CG Oncology has a short interest ratio ("days to cover") of 11.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in CG Oncology has recently increased by 2.04%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    CG Oncology does not currently pay a dividend.

  • Dividend Growth

    CG Oncology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    24.51% of the float of CG Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    CG Oncology has a short interest ratio ("days to cover") of 11.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in CG Oncology has recently increased by 2.04%, indicating that investor sentiment is decreasing.
  • News Sentiment

    CG Oncology has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for CG Oncology this week, compared to 5 articles on an average week.
  • Search Interest

    2 people have searched for CGON on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, CG Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $56,000.00 in company stock.

  • Percentage Held by Insiders

    Only 7.40% of the stock of CG Oncology is held by insiders.

  • Percentage Held by Institutions

    Only 26.56% of the stock of CG Oncology is held by institutions.

  • Read more about CG Oncology's insider trading history.
Receive CGON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CG Oncology and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CGON Stock News Headlines

Tax Drain Deadline: Protect Your Wealth Before September 15th
On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed professionals, retirees, and high-net-worth savers. But the wealthy aren’t just writing checks. They’re moving fast to protect capital and purchasing power using legal, IRS-compliant strategies. American Alternative Assets just released the Mar-A-Lago Accord, a free guide revealing how to reduce Q3 tax exposure and reposition wealth before it’s drained.tc pixel
See More Headlines

CGON Stock Analysis - Frequently Asked Questions

CG Oncology's stock was trading at $28.68 at the beginning of the year. Since then, CGON shares have decreased by 7.7% and is now trading at $26.4730.

CG Oncology, Inc. (NASDAQ:CGON) announced its quarterly earnings results on Friday, August, 8th. The company reported ($0.54) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by $0.05. CG Oncology had a negative trailing twelve-month return on equity of 19.37% and a negative net margin of 15,945.17%.

CG Oncology (CGON) raised $380 million in an IPO on Thursday, January 25th 2024. The company issued 20,000,000 shares at a price of $19.00 per share.

Top institutional shareholders of CG Oncology include Alliancebernstein L.P. (2.84%), Bank of America Corp DE (2.28%), Franklin Resources Inc. (1.95%) and Geode Capital Management LLC (1.75%). Insiders that own company stock include Hong Fang Song, Decheng Capital Global Life Sc, Corleen M Roche, Vijay Kasturi and Leonard E Post.
View institutional ownership trends
.

Shares of CGON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CG Oncology investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA) and Tesla (TSLA).

Company Calendar

Last Earnings
8/08/2025
Today
8/28/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CGON
Previous Symbol
NASDAQ:CGON
CIK
1991792
Fax
N/A
Employees
61
Year Founded
N/A

Price Target and Rating

High Price Target
$75.00
Low Price Target
$23.00
Potential Upside/Downside
+106.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
11 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.77)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$88.04 million
Net Margins
-15,945.17%
Pretax Margin
-23,245.19%
Return on Equity
-19.37%
Return on Assets
-18.72%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
22.15
Quick Ratio
22.15

Sales & Book Value

Annual Sales
$1.14 million
Price / Sales
1,763.25
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$8.79 per share
Price / Book
3.00

Miscellaneous

Outstanding Shares
76,250,000
Free Float
70,606,000
Market Cap
$2.01 billion
Optionable
Optionable
Beta
0.87
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:CGON) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners